The natural anticancer compound rocaglamide selectively inhibits the G1-S-phase transition in cancer cells through the ATM/ATR-mediated Chk1/2 cell cycle checkpoints

The Natural Anticancer Compounds Rocaglamides Inhibit the Raf-MEK-ERK Pathway by Targeting Prohibitin 1 and 2

(2012) Gernot Polier et al.   CHEMISTRY & BIOLOGY

CHK1 activity is required for continuous replication fork elongation but not stabilization of post-replicative gaps after UV irradiation

(2012) Ingegerd Elvers et al.   NUCLEIC ACIDS RESEARCH

Camera: a competitive gene set test accounting for inter-gene correlation

(2012) Di Wu et al.   NUCLEIC ACIDS RESEARCH

ATM activation in the presence of oxidative stress 

(2011) Zhi Guo et al.   CELL CYCLE

Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression

(2010) M Bleumink et al.   CELL DEATH AND DIFFERENTIATION

ATM Activation by Oxidative Stress

(2010) Z. Guo et al.   SCIENCE

Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression

(2009) J Y Zhu et al.   CELL DEATH AND DIFFERENTIATION

Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2

(2009) H Christian Reinhardt et al.   CURRENT OPINION IN CELL BIOLOGY

Cell cycle kinases as therapeutic targets for cancer

(2009) Silvia Lapenna et al.   NATURE REVIEWS DRUG DISCOVERY

Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol

(2009) Regina Cencic et al.   PLoS One

CDC25A Phosphatase: a Rate-Limiting Oncogene That Determines Genomic Stability

(2008) D. Ray et al.   CANCER RESEARCH

ATR: an essential regulator of genome integrity

(2008) Karlene A. Cimprich et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY